Tracers / [223Ra]Ra-RaCl2
[223Ra]Ra-RaCl2
Also written as [Ra-223]RaCl2
- Radionuclide
- Ra-223 t½ 16459 min
- Modality
- Therapy
- Production route
- —
- Stage
- approved
- Syntheses indexed
- 14
What it is
- Compound class
- bone-seeking radiopharmaceutical (radium dichloride, calcium-mimetic alpha emitter)
- Target / mechanism
- Calcium-mimetic alpha-emitter that localizes to bone metastases (bone-seeker) PMID 34163647
- Clinical application
- Treatment of bone metastases in metastatic castration-resistant prostate cancer PMID 36687439
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 42149170 2026 Radiat Environ Biophys |
| — | — | — | — | — | — | 41746558 2026 EJNMMI Radiopharm Chem |
| — | — | — | — | — | — | 36687439 2022 Front Med (Lausanne) |
| Manual synthesis | — | none | 95 ± 1.05% | >95% | macropa | 34163647 2021 Chem Sci The reaction was carried out at room temperature by mixing a solution of macropa with 3.7 kBq (0.1 μCi) of [223Ra]Ra2+ — Within 5 min at room temperature, [223Ra][Ra(macropa)] was formed with a radiolabeling efficiency (RL% ± SD) of 95 ± 1.05% (n = 5) (Fig. 2a) |
| — | — | — | — | — | — | 26573043 2015 Glob J Health Sci |
| — | — | — | — | >94% | UiO-66-NH2 MOF (mMOF) | 41452472 2026 ACS Appl Mater Interfaces |
| — | — | — | — | >94% | UiO-66-NH2 MOF (nMOF) | 41452472 2026 ACS Appl Mater Interfaces |
| — | — | — | — | — | — | 35717046 2022 Pract Radiat Oncol |
| — | — | — | — | — | — | 31096849 2019 Tumori |
| — | — | — | — | — | — | 28427834 2018 Appl Radiat Isot |
| — | — | — | — | — | — | 28216330 2017 Phys Med |
| — | — | — | — | — | — | 25301826 2014 Ann Pharmacother |
| — | — | — | — | — | — | 24604017 2014 Urologe A Ra-223 has been approved under the product name Xofigo\u00ae by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). |
| — | — | — | — | — | — | 24190979 2014 Clin Cancer Res |
Need this precursor?We can point you to suppliers for [223Ra]Ra-RaCl2, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 6 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 42149170: 'The radiopharmaceutical 223Ra-dichloride (Xofigo®) has been approved for palliative treatment of metastatic castration-resistant prostate cancer.'.